- 1 MIAI: Maturation of Immunity Against Influenza a German birth
- 2 cohort study with focus on the development of immunity against
- **3 respiratory viral infections**

12

- 5 Carina R. Hartmann<sup>1†</sup>, Robin Khan<sup>1†</sup>, Jennifer Schöning<sup>1</sup>, Maximilian Richter<sup>1</sup>, Maike Willers<sup>2</sup>,
- 6 Sabine Pirr<sup>2,3</sup>, Julia Heckmann<sup>1</sup>, Johannes Dirks<sup>1,4</sup>, Henner Morbach<sup>1,5</sup>, Monika Konrad<sup>1</sup>, Elena
- 7 Fries<sup>1</sup>, Magdalene Winkler<sup>6</sup>, Johanna Büchel<sup>6</sup>, Silvia Seidenspinner<sup>1</sup>, Jonas Fischer<sup>1</sup>, Claudia
- 8 Vollmuth<sup>1</sup>, Martin Meinhardt<sup>1</sup>, Janina Marissen<sup>1</sup>, Mirco Schmolke<sup>7,8</sup>, Sibylle Haid<sup>9</sup>, Thomas
- 9 Pietschmann<sup>3,9,10</sup>, Simone Backes<sup>11</sup>, Lars Dölken<sup>3,12</sup>, Ulrike Löber<sup>13-16</sup>, Thomas Keil<sup>17-19</sup>, Peter
- 10 U. Heuschmann<sup>18,20,21</sup>, Achim Wöckel<sup>6</sup>, Sagar<sup>22</sup>, Thomas Ulas<sup>23-25</sup>, Sofia K. Forslund-
- 11 Startceva<sup>13-15,26</sup>, Christoph Härtel<sup>1‡</sup> and Dorothee Viemann<sup>1-3,27\*</sup>‡
- 13 Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany
- <sup>2</sup> Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical
- 15 School, Hannover, Germany
- <sup>3</sup> Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany
- <sup>4</sup> German Center for Infection Research, Site Hamburg-Lübeck-Borstel-Riems, Hamburg,
- 18 Germany
- <sup>19</sup> Center for Primary Immunodeficiencies and Autoinflammatory Diseases (CIDA), University
- 20 Hospital Würzburg, Würzburg, Germany
- 21 <sup>6</sup> Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg,
- 22 Germany
- <sup>7</sup> Department of Microbiology and Molecular Medicine, University of Geneva, Rue Michel-
- Servet 1, Geneva, Switzerland
- <sup>8</sup> Center for Inflammation Research, Faculty of Medicine, University of Geneva, Geneva,
- 26 Switzerland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- <sup>9</sup> Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical
- Infection Research, a joint venture between the Helmholtz Centre for Infection Research
- and the Hannover Medical School, Hannover, Germany
- 30 <sup>10</sup> German Centre for Infection Research, Partner site Braunschweig-Hannover,
- 31 Braunschweig, Germany
- 32 <sup>11</sup> Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany
- 33 <sup>12</sup> Institute of Virology, Hannover Medical School, Hannover, Germany
- 34 Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
- 35 <sup>14</sup> Experimental and Clinical Research Center, a cooperation of Charité Universitätsmedizin
- Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
- 37 <sup>15</sup> Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin,
- Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- <sup>16</sup> DZHK (German Centre for Cardiovascular Research), Partner site Berlin, Berlin, Germany
- 40 <sup>17</sup> Institute of Social Medicine, Epidemiology and Health Economics, Charité
- 41 Universitätsmedizin Berlin, Berlin, Germany
- 42 <sup>18</sup> Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg,
- 43 Germany
- 44 <sup>19</sup> State Institute of Health I, Bavarian Health and Food Safety Authority, Erlangen, Germany
- 45 <sup>20</sup> Institute for Medical Data Science, University Hospital Würzburg, Würzburg, Germany
- 46 <sup>21</sup> Clinical Trial Centre Würzburg, University Hospital Würzburg, Würzburg, Germany
- 47 <sup>22</sup> Department of Medicine II (Gastroenterology, Hepatology, Endocrinology, and Infectious
- Diseases), Freiburg University Medical Center, University of Freiburg, Freiburg, Germany
- 49 23 Systems Medicine, German Center for Neurodegenerative Diseases (DZNE), Bonn,
- 50 Germany
- 51 <sup>24</sup> PRECISE Platform for Single Cell Genomics and Epigenomics, DZNE and University of
- Bonn, Bonn, Germany
- 53 <sup>25</sup> Genomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of
- 54 Bonn, Bonn, Germany

- 55 Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL),
- 56 Heidelberg, Germany

- 57 Center for Infection Research, University Würzburg, Würzburg, Germany
- These authors contributed equally to this work and share first authorship
- 59 ‡ These authors contributed equally to this work and share senior authorship
- \* Correspondence: viemann d@ukw.de

### **Abstract**

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

Respiratory viral infections (RVIs) are a major global contributor to morbidity and mortality. The susceptibility and outcome of RVIs are strongly age-dependent and show considerable interpopulation differences, pointing to genetically and/or environmentally driven developmental variability. The factors determining the age-dependency and shaping the age-related changes of human anti-RVI immunity after birth are still elusive. We are conducting a prospective birth cohort study aiming at identifying endogenous and environmental factors associated with the susceptibility to RVIs and their impact on cellular and humoral immune responses against the influenza A virus (IAV), respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The MIAI birth cohort enrolls healthy, full-term neonates born at the University Hospital Würzburg, Germany, with follow-up at four defined time-points during the first year of life. At each study visit, clinical metadata including diet, lifestyle exposures, sociodemographic information, and physical examinations, are collected along with extensive biomaterial sampling. Biomaterials are used to generate comprehensive, integrated multi-omics datasets including transcriptomic, epigenomic, proteomic, metabolomic and microbiomic methods. The results are expected to capture a holistic picture of the variability of immune trajectories with a focus on cellular and humoral key players involved in the defense of RVIs and the impact of host and environmental factors thereon. Thereby, MIAI aims at providing insights that allow unraveling molecular mechanisms that can be targeted to promote the development of competent anti-RVI immunity in early life and prevent severe RVIs.

- Trial registration number: DRKS00034278
- 85 **Keywords:** Birth cohort, respiratory viral infection, IAV, RSV, SARS-CoV-2, multi-omics data,
- 86 anti-viral immunity, microbiota

### INTRODUCTION

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Several epidemiological studies demonstrate strong age-dependent differences for the susceptibility and outcome of respiratory viral infections (RVIs) (1). Prime examples are infections with the respiratory syncytial virus (RSV), the influenza A virus (IAV) and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RSV is the most common cause of severe respiratory infection in infants, leading to over 3 million hospitalizations and around 66,000 deaths worldwide each year (2-4). Remarkable age-related differences in innate cytokine responses following recognition of RSV have been observed (3, 5), suggesting a critical role of the host response in the disease pathology and clinical outcome. RSV infects virtually all children by the age of three years and then repeatedly infects throughout life. Therefore, host factors of the epithelial barrier and the innate immune system might define the susceptibility to RSV infections, while adaptive immunity, which underlies profound maturational changes during early life, might rather contribute to the severity of the course of an established RSV infections but does not necessarily acquire longlasting protective memory. In contrast to the age profile of RSV infections, work from the Global Burden of Disease Study showed that the population attributable fraction of IAV-caused mortality as well as morbidity are lowest in children under 5 years of age and highest in mid-aged adults (30-40 years) (6). The age-dependent differences in the clinical outcome of IAV infection are not fully explained by pre-existing comorbidities or maternal transfer of adaptive anti-influenza immunity to infants and point to hitherto unidentified immunological peculiarities that protect infants against IAV. Children have also less severe symptoms when infected with SARS-CoV-2 (7, 8). Several hypotheses for the age-related difference in the severity of coronavirus disease 2019 (COVID-19) are discussed, such as more robust type I interferon (IFN) response, more effective T cell immunity (9), and higher expression of SARS-CoV-2 sensing receptors and inflammatory baseline activation of pediatric compared to adult airway epithelial cells (AECs) (10-12). However, the causes and biological meaning of such differential programming of anti-viral immunity at different ages and in dependency of the type of virus remains elusive.

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

Apart from the age dependency there is also strong heterogeneity in the course and outcome of RVIs among individuals of same age, pointing to considerable genetic variability or differential development of immunity in concert with their environment. Understanding interindividual variation and its causes has important implications for targeting patients for escalation of care, inclusion in clinical trials, and individualized medical therapy including vaccination. Besides clear biological differences such as age, sex, race, presence of comorbidities, and genetic variation, differential maturation of immunity during environmental adaptation after birth might result in a different education and regulation of immune responses against RVIs. In humans, the key factors influencing the reprogramming of immunity towards RVIs are still poorly defined and comparison of their effect sizes is long overdue. A myriad of data has demonstrated that the immune system of the fetus and infant is characterized by a high plasticity, which comes with a high susceptibility to lifelong imprinting effects from environmental cues. Over the past two decades strong evidence accumulated that the composition and function of the human microbiome play a particularly critical role for the development of immunity and overall health (13, 14). Several longitudinal studies revealed aberrant trajectories of upper respiratory microbiota during infancy that are associated with an increased susceptibility to respiratory tract infections. These particularly include delayed and low abundance of Corynebacterium and Dolosigranulum species and high abundance of Moraxella, Haemophilus or Streptococcus species (15-19). However, our knowledge on how exactly these strains impede respective promote immunity against respiratory viruses remains largely elusive. Furthermore, the gut microbiota seems to have impact on the development of immunity against RVIs. Though hitherto only shown in mice, gut microbiota-derived short chain fatty acids protected against RSV infections by improving type 1 IFN responses and increasing IFNstimulated gene expression in lung epithelial cells (20), while the presence of segmented filamentous bacteria protected against IAV, RSV as well as SARS-CoV-2 infection by priming resident alveolar macrophages (21). In humans, only an association between specific gut microbial profiles and RSV disease severity in hospitalized infants has been detected so far (22). However, the molecular pathways of this gut-lung axis and their delicate dependency on age and interactions with environmental exposures (e.g., diet, passive smoke, pollutants) remain unclear. Several clinical trials contributed to an increasing body of evidence that probiotics might be an option to lower the susceptibility to RVIs (23-25); however, many questions on how exactly (e.g., strain dependency), to what extent individualized (e.g., age dependency, host microbial background) and when (e.g., neonatal window) to use such interventions are still open (26–28). Addressing these remaining knowledge gaps could enable modulation of airway and gut microbial communities and their metabolic patterns, presenting a potential therapeutic strategy to prevent or ameliorate severe RVIs. In summary, at specific developmental stages opposite infectious susceptibility can be observed depending on the causative viral strain. Moreover, different trajectories of immune maturation after birth can lead to strong inter-population differences in the susceptibility to severe RVIs. To understand which specific age- and microbiota-related immunological differences and temporal changes are most relevant across various RVIs, we need a comprehensive view of the longitudinal development of anti-RVI immunity and the impact of and interplay with key factors involved. This requires the establishment of a tailored birth cohort study that investigates longitudinally and in-depth the development of the function of the airway epithelial barrier site and professional innate and adaptive immune cells in newborns against different respiratory viruses. Simultaneously, the study will assess the potential clinical and environmental factors including the status of the respiratory and gut microbiota that may influence these processes. Such comprehensive data sets are mandatory for the development of novel interventions that either target the host or the microbiota to early prevent or successfully treat severe RVIs in the future.

#### Aim

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

The MIAI study hypothesizes that: (i) the course and outcome of RVIs among individuals is related to the large variability in maturational trajectories of anti-viral immunity and (ii) environmental, lifestyle and dietary factors influence the early imprinting of anti-viral immunity in ways that either promote an increased susceptibility to RVIs and their complicated course

or support protective patterns (Figure 1). To verify these hypotheses, the MIAI birth cohort has been set up and includes healthy newborn infants born at term and their families. We aim at a comprehensive characterization of age-related differences and changes in the human immune system of the participants with a focus on the function of the cellular key players involved in the establishment of infections with RSV, IAV and SARS-CoV-2. Detailed phenotyping including factors potentially promoting and confounding the individual immune trajectory will be established; in particular, we are interested in the role of the developing microbiome on priming and regulating anti-RVI immunity. The specific aims of our study are:

- Aim 1. To characterize the developmental changes of innate and adaptive immune responses to RVIs during the first year of life.
- Aim 2. To determine the impact of sociodemographic background, clinical histories and environmental exposures including lifestyle, vaccinations and dietary factors on the trajectories of immune responses toward RVIs.
- Aim 3. To elucidate whether there is a link between the microbiome establishment and anti-RVI immunity developing after birth.

In brief, we aim to provide insights into age-dependent programming and early-life changes of immunity toward RVIs in humans, highlighting training, priming and acquisition of tolerance, by collecting granular clinical metadata and performing comprehensive unbiased immune phenotyping using multi-omics approaches (Figure 2).

### **METHODS AND ANALYSIS**

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Study design, cohort recruitment and follow-up visits

The MIAI study is a single center, population-based birth cohort study at the University Hospital Würzburg. MIAI enrolls healthy newborn infants and their families and follows them throughout the first year of life (Figure 2). The ongoing recruitment started in February 2022 reaching about 170 infants up to date (with a 2-month interruption of recruitment due to an interim shortage of staff) (Table 1). Inclusion criteria encompass full-term, healthy neonates (37<sup>+0</sup> to 41<sup>+6</sup> gestational weeks) born at the perinatal center of the University Hospital Würzburg, Germany, whose families' residency is located in the city of Würzburg or its administrative district. Exclusion criteria are amniotic infection syndrome, early-onset neonatal sepsis, congenital malformations, primary immunodeficiency or metabolic diseases, and remarkable language barriers. We will however do an earnest attempt to provide understandable information on our study in the native language of parents whose infants would be eligible thus aiming for a population-representative sample. The study recruits a convenience sample cohort; as such, the sample size is not calculated. The first study visit is performed at the University Hospital for Women's health and Obstetrics Würzburg, Mothers of eligible infants are approached in the first three days after birth. After obtaining written informed consent from the parents, the baseline assessment takes place during the hospital stay of mother and infant. The follow-up appointments are performed one month, six months and one year after birth at the dedicated Pediatric Clinical Study Outpatient Service at the University Children's Hospital Würzburg. We are planning to track the study participants for long-term follow-up during childhood. Overall, the acceptance of our study design with its follow-up appointments and sample collection is high with a relatively low drop-out rate of about 8% after one year as of May 2024, including families that relocated outside of Würzburg and its administrative district. The baseline characteristics of infants enrolled so far are presented in Table 1. Overall, the proportions of female and male infants are equal and the mean gestational age and birth weight appropriate and in line with the inclusion criterium of full-term birth. The largest number of

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

neonates was born vaginally (VD, 62%). Cesarean sections (CS, 38%) were in the majority of CS secondary (60%), i.e. after rupture of membranes, and only a minor part elective (37%) or due to emergency (3%). Half of the MIAI infants have older siblings which of 86% are visiting child care or school. The exposure to nicotine due to smoking family members affects 22% of the MIAI infants and 22% of the families have pets. The distribution of rural compared to urban living environments is even. Characteristic values of pregnancy histories from infants enrolled in MIAI including maternal factors potentially impacting on the child's RVI immunity are listed in Table 2. The mean weight gain during pregnancies was 14 kg with a mean body mass index (BMI) of 29.4 (± 5.8) at birth, not exceeding the limits recommended by obstetricians (29). The smaller number of mothers were primigravida (38%). During routine prenatal screenings, gestational diabetes mellitus was detected in 12% and gestational hypertension in 1.8%. The proportions of mothers vaccinated and/or recovered from IAV and SARS-CoV-2 infections are 48% and 97%, respectively. For the Influenza status, 52% of mothers did not know whether they have experienced an IAV infection, while only 3% of mothers did not know their SARS-CoV-2 status. Table 3 summarizes anthropometric, medical and sociodemographic characteristics of participating parents. The mean age of mothers and fathers from the entire cohort is 32.8 (± 4.5) years and 35.3 (± 5.4) years, respectively. The medical history data of the parents showed that 52% of the mothers and 24% of the fathers reported somatic disorders including allergies, psoriasis, neurodermatitis, cardiovascular disorders, obesity, thyroid disorders, as well as benign and malignant tumors. Mental disorders were indicated by 8.4% of the mothers and 6.0% of the fathers. About 84% of the participating parents reported a Western European ethnicity and 79% of the mothers and 71% of the fathers were higher educated.

#### Clinical data collection and data management

Clinical data collection in MIAI is accomplished using tailored case report forms (CRFs) at each study timepoint (Table 4). At baseline, the histories of pregnancy and perinatal events are documented upon enrollment. From mothers and fathers, detailed information on demographic

and psychosocial background, family histories and lifestyles are requested. Particular attention is paid on maternal respiratory infections and vaccinations, before and during pregnancy. For the infants, we document at each study visit body measurements, the histories of vaccinations, infections, antibiotics including days of treatment, medications including inhalations, episodes of wheezing, skin rashes, allergies, hospital stays, and surgical procedures, diets including dietary supplements, lifestyle including the number of siblings and further household members, pets, residence (rural/urban), and stays abroad. In addition to the questionnaires, the MIAI pediatrician performs a comprehensive physical examination of the infant at each study appointment to monitor the overall health status including growth, physical and psychomotor development (Table 4). To align with the FAIR data principles (Findable, Accessible, Interoperable, Reusable), the collected clinical data is managed to ensure high standards of data quality and usability. For data protection reasons, the participant's data is pseudonymized and assigned a unique study ID, which is documented in a separate and password-secured data file accessible by authorized MIAI staff only. A separate external data file is used as a contact database for tracking study participations and invitations to follow-up. The pseudonymized clinical data are double-entered into a password-secured REDCap database hosted at the Institute of Clinical Epidemiology and Biometry, University of Würzburg (IKE-B). Local password-secured copies of the database are generated. The database provides a comprehensive log/audit feature to record data input and changes based on user and time/date. By adhering to these FAIR principles, MIAI enhances the value of its clinical data, promoting its use in further research while maintaining high standards of data security and participant confidentiality.

#### Collection and storage of biomaterials

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

At each appointment, biomaterials from mothers (breast milk) and child (nasal brushes, pharyngeal swabs, skin swabs, stool, blood) are collected according to the schedule illustrated in Figure 3. We have chosen these timepoints to afford serial profiling while minimizing burden. Collection and storage of biomaterials are performed according to established standard

operating procedures (SOPs). After collection, biomaterials are immediately transferred to the adjacent laboratory for processing and biobanking.

## Breast milk samples

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

As long as the mother is breastfeeding, breast milk/colostrum are sampled at each appointment. First, cells are pelleted by centrifugation and the skim milk and the fat layer are removed. The skim milk and fat layer are once more sharply centrifuged and aliquoted for storage at -80°C for later proteomic and microbial studies. The cells are cryopreserved at -152°C following multiple washing steps for later single cell studies.

#### Nasal brushes

Nasal brushing is an established method in pediatric pulmonology, e.g. essential for diagnosing primary ciliary dyskinesia, and provides a robust technique to generate AEC cultures in term and even preterm infants (12, 30). Brushings are taken from the inferior nasal turbinate using sterile interdental brushes (Rossmann, ISO sizes 4 or 5). After sampling, brushes are immediately placed in sterile tubes with transport medium (MEM without additives, antibiotics and antimycotics) and processed within 1 h of collection. Brushes are carefully moved up and down to scrape the cells off and collect them into the transport medium. Next, cells are centrifuged and supernatants stored as "nasal secretions" at -80°C for later proteomic, cytokine and microbiota profiling. The AECs are first expanded in submersion according to established protocols (31, 32) and then cryopreserved at -152°C. Some of the expanded AECs are directly differentiated at the air-liquid-interface (ALI) into a mature pseudostratified respiratory epithelium as described previously (32) and used for infection experiments with RSV (RSV-A-ON1, HRSV/A/DEU/H1/2013) (33) and IAV (H1N1, A/Netherlands/602/2009). Infections with SARS-CoV-2 (SARS-CoV-2/human/DEU/REGS-200701-CA/2020) are done later under biosafety level 3 conditions using cryopreserved AECs for differentiation at ALI. After infection, AECs are harvested and subjected to immediate FACS studies capturing cell composition and cell quality, generation of total RNA lysates for the analysis of transcriptomes (bulk RNASeq) and viral loads (qRT-PCR), and standardized cryopreservation (34) for later single cell (scRNASeq) and epigenetic (ATACSeq) studies. Apical and basolateral

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

supernatants are stored at -80°C for later analyses of proteome (Mass Spectrometry) and cytokine (FACS-based multiplex assays) profiles and virus plaque assays assessing viral progeny. This approach aims at generating data from each MIAI participant regarding individual airway epithelial immune responsiveness and function toward RVIs at birth and at 1 year of life (Figure 3). The strategy is based on previous reports that ALI-AEC models established from human primary AECs recapitulate well the *in vivo* phenotype of the airway epithelium (12, 35, 36). Pharyngeal and skin swabs Three pharyngeal swabs and two skin swabs are collected, respectively. One of the respective swabs is transferred to a sterile tube containing sterile PBS with 10% BSA (for protein stabilization) and stored at -80°C for protein and cytokine measurements. The other two respective swabs are stored at -80°C without additives for later DNA isolation and microbiota studies (16S rRNA sequencing and shotgun metagenomics). Stool samples Stool samples are collected by the MIAI staff from diapers and immediately transferred to -80°C. In cases where stool collection at the respective appointments not succeeds, we use samples collected and stored at 4°C by the parents at the evening before or the morning of the follow-up appointment for biobanking at -80°C. Three 1.5 ml tubes are filled with stool, respectively, one of which contains 600 µl DNA/RNA shield (Zymo Research, California, USA) to preserve nucleic acids for 16S rRNA sequencing and metagenomics studies. The other two stool aliquots are stored without additives and used for the extraction and analysis of immunoactive proteins such as S100-alarmins (37) and cytokine profiles according to established protocols (38). Blood samples Cord blood is collected preemptively from all eligible neonates but only processed when parents agree on participation in the MIAI study. If no consent is given, cord blood samples are discarded. The volumes of drawn peripheral venous blood samples align to the pediatric quidelines of the European Medical Agency, which recommends that blood collection for

research purposes should be at maximum 1% of total blood volume (i.e., 0.8 ml/kg body weight). At the first sampling timepoint, we seek to combine blood collection in MIAI with the routine newborn screening taken between 36 and 72 hours of life. Blood samples are processed within 1 h after collection. The serum samples are stored at -80 °C and used for cytokine, metabolome and serological studies including quantification of antibody titers against RSV, IAV and SARS-CoV-2. From EDTA samples, peripheral blood mononuclear cells (PBMCs) are isolated and profiled using established multidimensional FACS panels (39–43). One part of isolated PBMCs is cryopreserved at -152°C for later single cell, epigenetic and experimental studies (e.g., analysis of T and B cell subsets and receptor repertoires including virus-specific effector T cells). To avoid functional impairment of the myeloid cells due to cryopreservation, monocytes are directly isolated from the other part of isolated PBMCs as described previously (44, 45) and infected with RSV and IAV. After infection, total RNA lysates are generated and culture supernatants harvested and both stored at -80°C for the analysis of transcriptomes, viral loads, proteome and cytokine profiles, and viral progeny.

## Data analysis and statistics

Omics data analysis in MIAI will be performed on different levels as results from transcriptomics including lymphocyte receptor repertoires, epigenomics, 16S rRNA gene and shot-gun metagenomics sequencing, breast milk and serum metabolomics and proteomics including cytokine and serologic profiles. We aim at subjecting full longitudinal sample series from 400 infants to study the omics profiles. Given the longitudinal nature of our study set up, samples previewed for these studies will be randomized to reduce batch effects. Initially, each omics dataset will undergo individual analysis to elucidate its unique characteristics. Subsequent exploratory analyses will determine the necessity of batch correction for each dataset. If required, corrections will be implemented using ComBat batch method to normalize across multiple analytical runs and WithinVariation function implemented in the R mixOmics package and to normalize features as change over time within each child. Post-correction, we will validate that the biological variability is preserved and that no artifacts were introduced. We

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

will perform omics-specific statistical analyses and co-expression network analyses using hCoCena (46, 47) to identify and characterize differential subgroups with greater precision. All data generated including standardized meta-data will be quality-controlled and gathered within a unified framework following standards for omics and clinical measurement representation, allowing within-study integration and comparative analysis with previous studies according to FAIR data principles. Differential trajectorial endotypes will be identified using KmL (k-means for longitudinal data) clustering. To determine the optimal number of clusters (k), we will run 1000 permutations, utilizing the Harabasz criterion (Calinski-Harabasz index) to evaluate clustering validity. This methodology will facilitate a nuanced, continuous classification of patients, transcending binary categorization and allowing also for a more detailed representation of endotypic variation. Specialized software packages for dataset-specific imputation will be employed to address any missing data points, ensuring robust classification of immune and microbiome trajectories across the cohort. Advanced statistical methods and machine learning algorithms will be integrated into the analysis pipeline to enhance the precision and reliability of the endotype classification. To elucidate the relationships between specific immunotypes, respiratory or gut microbiome profiles, environmental factors, and clinical outcomes, we have created two specialized software tools, metadeconfoundR (48) and longdat (49). These tools enable comprehensive mixed omics data analysis while managing the complex interplay of numerous demographic. therapeutic, and disease-related variables. MetadeconfoundR is designed to facilitate the identification of biomarkers within cross-sectional multi-omics medical datasets, while carefully accounting for confounders. Initially, it identifies significant associations between features and metadata using nonparametric tests such as the Mann-Whitney U test. Subsequently, it assesses and adjusts for confounding effects among these metadata variables through posthoc nested linear model comparison. Importantly, metadeconfoundR can integrate previously established knowledge of confounders, such as drug associations from the MetaCardis cohort, into its analysis. This inclusion aids in maintaining robust conclusions even when new datasets

lack the statistical power to independently identify these confounders. LongDat, meanwhile, is an R package tailored for analyzing longitudinal multivariable data, effectively handling a wide array of covariates. It distinguishes direct from indirect intervention effects and identifies key covariates that may act as mechanistic intermediates. Although primarily focused on longitudinal microbiome data, LongDat's versatility allows application to various data types including binary, categorical, and continuous data. Comparative testing against other analytical tools like MaAsLin2, ANCOM, Igpr, and ZIBR has demonstrated LongDat's superior performance in terms of accuracy, runtime, and memory efficiency, making it an ideal choice for high-dimensional longitudinal studies where multiple covariates are a consideration.

### Next steps and outlook

To gain a comprehensive picture of how immune profile development including cellular responses to RVIs varies amongst individuals, we are in the process to analyze the biomaterials by a multi-omics approach. This encompasses transcriptomic, epigenomic, metagenomic, and metabolomic layers. These data are extended by cellular phenotyping using high-dimensional flow cytometry and the innate and adaptive immune responses to IAV, RSV and SARS-CoV-2. Next, the omic phenotypes will be integrated with large clinical data sets. As most of the one-year-old infants have not yet attended a day care center, which is an important contributor to microbiome maturation (50, 51), we continue the longitudinal assessment of MIAI participants by the means of annual questionnaires until regular follow-up at early school age. Our long-term vision is to disentangle the role of early programming of anti-viral immunity for the susceptibility to RVIs and also non-communicable diseases such as asthma, obesity or autoimmune disorders. Future plans include data collection of participants until 12 years of participants' age, which would allow to investigate how differences in omics immune and microbiome endotypes translate into population differences in clinical outcomes and susceptibility to RVIs.

### **DISCUSSION**

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

Considering the impact of the recent SARS-CoV-2 pandemic (52) or previous pandemics and epidemics due to IAV and RSV on human health (6, 53, 54), our knowledge about the ontogeny of immunity towards RVIs and the factors determining the developmental variability is little. Except for pre-existing co-morbidities and primary immunodeficiencies, hitherto, only the acquisition of autoantibodies against type I IFNs (55) and genetic variants, particularly in cytokines and pattern recognition receptors (56), could be linked to severe RVI cases, though only in a minor proportion of RVIs, and explain inter-population variability of anti-RVI immunity. We recently initiated the recruitment of a birth cohort of healthy newborn infants in Germany that has been designed to investigate in particular the development of immunity towards RVIs in early childhood. The data shown in the present manuscript reflect an initial characterization of the MIAI cohort. Comparison of the structure of the current MIAI cohort with those reported from other recruiting maternal or term infant birth cohorts in Europe show similar distributions and rates of e.g. sex, gestational age, birth weight, multiple births, mode of delivery, first-time mothers, number of siblings, maternal age and BMI, gestational diabetes and hypertension, infections during pregnancy, and parental education and smoking (57-60). It is gratifying that in MIAI the drop-out rate of 8% is low in comparison to other birth cohorts which also perform repeated collection of biomaterials, e.g., the SweMaMi cohort (59) and KUNO-Kids cohort (57) that recorded 40-50% of lost 1-year follow-ups. Hence, we assume that the MIAI cohort will be representative of an infant population in Central Europe. The common immunological finding in severe IAV, RSV and SARS-CoV-2 related infectious diseases is an exceeding cytokine release (61-64), suggesting a strong involvement of a systemic inflammatory response due to a lack of viral clearance at the epithelial barrier site or its breakage. Therefore, our first research focus in MIAI will lay on the age-dependent immunological profiling of the airway epithelium and blood monocytes, as key mediators of systemic cytokine storms during severe RVIs (65, 66), and the identification of demographic, clinical, environmental, lifestyle and dietary factors on the trajectories of their immune responsiveness toward RVIs. Interestingly, a previous study revealed a link between a low

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

susceptibility of monocytes to IAV infections and high basal monocyte activation, which the authors assumed to be driven by environmental factors and/or weak-effect genetic variants that remain to be identified (67). A plethora of studies report on distinct gut and respiratory microbiota compositions that are associated with an increased risk of RVIs with either IAV, RSV or SARS-CoV-2 (13, 15, 16, 18–20, 22, 68–70). How exactly such reported microbiota profiles influence anti-RVI immunity remains largely elusive. To what extent the developmental changes of the microbiota shape the postnatal ontogeny of the development of anti-RVI immunity is even less understood. The MIAI study will help to characterize differential trajectories of anti-RVI immunity and improve our knowledge about influencing factors, in particular the influence of the gut and respiratory microbiota. The strength of the MIAI study is the population-based approach and the standardized in-depth longitudinal characterization of healthy individuals at birth and the comprehensive analysis of preserved biomaterials. The usage of cutting-edge multi-omics technology for the generation of longitudinal immune-microbiome profiles combined with functional profiling of the cellular immune response against RVIs make this cohort study a unique approach. Finally, by ensuring that the multi-omics-based profiles are integrated with highly granular clinical information, we are confident to identify factors that either promote or impede the development of immunity against RVIs. As in other population-based studies, we observe a bias toward high socioeconomic status among MIAI participants. Technically, the study has its limitation in the standardization of stool sample collection as sometimes home sampling is required, which precludes immediate freezing at -80°C as warranted by on-site visit sampling through the staff. With respect to clinical information, the study would benefit from an app-based monitoring that allows immediate reporting of acute infections that in case of respiratory symptoms then would prompt viral diagnostics. We aim at a timely implementation of this important add-on. In conclusion, the MIAI birth cohort study expects to generate data that give a holistic picture on the variability of the maturation of immunity towards RVIs in early life and identify host and environmental factors that influence the trajectory. By linking differential trajectories along with clinical information on incidences and outcomes of RVIs to specific immune features, MIAI will pave the way for in-depth elucidation of molecular mechanisms, which is the basis for the development of age-specific host-directed treatment strategies against severe courses of RVIs (e.g., (anti-)cytokine biologicals, tailored cell- or RNA-technology-based therapies). Of particular importance will be the identification of factors shaping anti-RVI immunity, as this is essential to design personalized interventions such as metabolic, probiotic and/or dietary measures that promote developing competent anti-RVI immunity in early life thus preventing severe RVIs in the long term.

#### ETHICS AND DISSEMINATION

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

This study was reviewed and approved by the Institutional Review Boards of the University of Würzburg (no. 13/22 z-am). The study is also registered on the German Clinical Trials Register (DRKS). The MIAI cohort is being conducted in compliance with all pertinent legislation and directives and following the guidelines on human biobanks for research and other relevant directives on research ethics. All parents have before inclusion signed informed consent in accordance with the Declaration of Helsinki II. Special emphasis is placed on privacy and safety of data. The proposed research is anticipated to generate a significant body of knowledge of interest to a wide range of stakeholders, from the clinical (pediatricians and other health professionals) to the research community but also to the public. Hence, a multilayered dissemination strategy will be followed and builds on cross-media communication to reach the specific target groups through their preferred media and information platforms. Local, national and international meetings and publication in peer-reviewed medical journals and via websites are used to inform for the scientific community. Once a year, study participants and healthcare professionals are invited by the study team to join online video meetings where they can discuss medical questions and pose any questions or comments on the study procedures. In addition, participating families will be provided with a copy of this publication to disseminate the MIAI study results.

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

**Acknowledgements** We would like to extend our gratitude towards families including the mothers, fathers and their infants included in the study, the sample collection team and recruitment team. This study would not have been possible without the work of a large group of staff members from the different departments. In particular, we acknowledge the contributions of the student assistants Lucia Baumgartner, Theresa Wurm and Leon Fagner, the entire team of midwives and the maternity unit including the lactation specialists. **Author contributions** Study design: MW, SP, CH, DV. Project management: CRH, CH, DV. Recruitment: RK, CRH, MK, EF, JF, MW, JB, CV, MM, JM, AW, DV. Biobanking: JS, MR. Data management: RK, CRH, MW, SP, MK, EF, JF, CV, MM, JM, TK, PUH, DV. Experiments: JS, MR, MW, JH, JD, HM, SS, MS, SH, TP, SB, LD, Sagar, TU, SKF-S. Data analysis: CRH, MW, SP, JH, JD, HM, SB, UL, Sagar, TU, SKF-S, DV. Data interpretation: CRH, MW, SP, JH, JD, HM, MS, SH, TP, SB, LD, UL, Sagar, TU, SKF-S, CH, DV. Writing: RK, UL, TU, CH, DV. Editing and revising: all authors. Funding acquisition: CH, DV. **Competing interests** The other authors declare no competing interests. **Funding** This work is supported by grants from Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) to DV (VI 538-9-1), CH (HA-6409-5-1) and TU (UL 521/1-1). The following other funding sources support the project: the Federal Ministry of Education and Research (BMBF) to SP, CH and DV (PROSPER; 01EK2103B and 01EK2103A, respectively); the DFG to SP (PI 1512/1-3) and DV (VI 538/6-3); the DFG SFB 1583/1 ("DECIDE") project number 492620490 to DV and SB; the DFG TRR 359 ("PILOT") project number 491676693 to

DV; the DFG Germany's Excellence Strategy – EXC 2155 'RESIST' – Project ID 390874280 to DV and TP; the BMBF Advanced Clinician Scientist Program ("INTERACT", project number 01EO2108) to HM.

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

FIGURE LEGENDS Figure 1. Hypothesis of the MIAI study. The hypothesis of the MIAI study is that the maturation of anti-viral immunity toward RVIs in early life underlies a large developmental variability, which is imprinted by clinical and environmental factors such as dietary habits, lifestyle, and particularly the composition and function of the co-evolving respiratory and gut microbiota. Figure 2. Design MIAI study. The MIAI study encompasses four phases starting with recruitment of term healthy infants and follow-up visits at defined timepoints. At each appointment, clinical data and biomaterials are collected for storage and/or usage in ex vivo respiratory viral infection models. Multi-omics datasets will be generated including immune profiles, transcriptomics, epigenomics, proteomics, metabolomics and microbiomics. To gain clinical and scientific knowledge, overall integration of mixed omics data shall enable participant stratification based on marker patterns linking to RVI susceptibility and reveal host and environmental factors imprinting anti-RVI immunity in the first year of life. Figure 3. Collection of biomaterials in MIAI. Biomaterials collected in the MIAI cohort include breast milk, nasal brushes and secretions, pharyngeal swabs, skin swabs, stool, cord blood and peripheral blood (EDTA and serum). They are obtained at the defined study time points, i.e. either at day 1-3 and/or day 30 of life and/or at 6 months and/or 1 year following birth. (Created with BioRender.com)

### REFERENCES

- 1. Zhu G, Xu D, Zhang Y, Wang T, Zhang L, Gu W, et al. Epidemiological characteristics of
- four common respiratory viral infections in children. Virol J (2021) **18**:10.
- 555 doi:10.1186/s12985-020-01475-y
- 2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden
- of acute lower respiratory infections due to respiratory syncytial virus in young children: a
- systematic review and meta-analysis. *Lancet* (2010) **375**:1545–55. doi:10.1016/S0140-
- 559 6736(10)60206-1
- 3. Openshaw PJ, Chiu C, Culley FJ, Johansson C. Protective and Harmful Immunity to RSV
- Infection. *Annu Rev Immunol* (2017) **35**:501–32. doi:10.1146/annurev-immunol-051116-
- 562 052206
- 563 4. Shi T, McAllister DA, O'Brien KL, Simoes EA, Madhi SA, Gessner BD, et al. Global,
- regional, and national disease burden estimates of acute lower respiratory infections due
- to respiratory syncytial virus in young children in 2015: a systematic review and modelling
- study. *Lancet* (2017) **390**:946–58. doi:10.1016/S0140-6736(17)30938-8
- 567 5. Smyth RL, Openshaw PJ. Bronchiolitis. *Lancet* (2006) **368**:312–22. doi:10.1016/S0140-
- 568 6736(06)69077-6
- 6. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to
- influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of
- 571 Disease Study 2017. Lancet Respir Med (2019) **7**:69-89. doi:10.1016/S2213-
- 572 2600(18)30496-X
- 573 7. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe Acute
- Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and
- 575 Adolescents: A Systematic Review. JAMA Pediatr (2020) 174:882-9.
- 576 doi:10.1001/jamapediatrics.2020.1467
- 577 8. Zhang C, Gu J, Chen Q, Deng N, Li J, Huang L, et al. Clinical and epidemiological
- 578 characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series.
- 579 *PLoS Med* (2020) **17**:e1003130. doi:10.1371/journal.pmed.1003130

- 9. Chou J, Thomas PG, Randolph AG. Immunology of SARS-CoV-2 infection in children. *Nat*
- 581 *Immunol* (2022) **23**:177–85. doi:10.1038/s41590-021-01123-9
- 10. Loske J, Röhmel J, Lukassen S, Stricker S, Magalhães VG, Liebig J, et al. Pre-activated
- antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in
- 584 children. *Nat Biotechnol* (2022) **40**:319-324. doi:10.1038/s41587-021-01037-9
- 11. Yoshida M, Worlock KB, Huang N, Lindeboom RG, Butler CR, Kumasaka N, et al. Local
- and systemic responses to SARS-CoV-2 infection in children and adults. *Nature* (2022)
- 587 **602**:321–7. doi:10.1038/s41586-021-04345-x
- 12. Woodall MN, Cujba A-M, Worlock KB, Case K-M, Masonou T, Yoshida M, et al. Age-
- specific nasal epithelial responses to SARS-CoV-2 infection. *Nat Microbiol* (2024) **9**:1293-
- 590 1311. doi:10.1038/s41564-024-01658-1
- 13. Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. *N Engl*
- 592 *J Med* (2016) **375**:2369–79. doi:10.1056/NEJMra1600266
- 14. Di Simone SK, Rudloff I, Nold-Petry CA, Forster SC, Nold MF. Understanding respiratory
- 594 microbiome-immune system interactions in health and disease. *Sci Transl Med* (2023)
- 595 **15**:eabq5126. doi:10.1126/scitranslmed.abq5126
- 15. Biesbroek G, Tsivtsivadze E, Sanders EA, Montijn R, Veenhoven RH, Keijser BJ, et al.
- 597 Early respiratory microbiota composition determines bacterial succession patterns and
- respiratory health in children. Am J Respir Crit Care Med (2014) 190:1283–92.
- 599 doi:10.1164/rccm.201407-1240OC
- 16. Bosch, Astrid A T M, de Steenhuijsen Piters, Wouter A A, van Houten MA, Chu, Mei Ling
- J N, Biesbroek G, Kool J, et al. Maturation of the Infant Respiratory Microbiota,
- 602 Environmental Drivers, and Health Consequences. A Prospective Cohort Study. Am J
- 603 Respir Crit Care Med (2017) **196**:1582–90. doi:10.1164/rccm.201703-0554OC
- 17. de Steenhuijsen Piters, Wouter A A, Binkowska J, Bogaert D. Early Life Microbiota and
- Respiratory Tract Infections. Cell Host Microbe (2020) 28:223–32.
- doi:10.1016/j.chom.2020.07.004

- 18. de Steenhuijsen Piters, Wouter A A, Watson RL, Koff EM de, Hasrat R, Arp K, Chu, Mei
- 608 Ling J N, et al. Early-life viral infections are associated with disadvantageous immune and
- 609 microbiota profiles and recurrent respiratory infections. *Nat Microbiol* (2022) **7**:224–37.
- doi:10.1038/s41564-021-01043-2
- 19. Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, et al. The infant nasopharyngeal
- 612 microbiome impacts severity of lower respiratory infection and risk of asthma development.
- 613 *Cell Host Microbe* (2015) **17**:704–15. doi:10.1016/j.chom.2015.03.008
- 20. Antunes KH, Fachi JL, Paula R de, Da Silva EF, Pral LP, Dos Santos AÁ, et al. Microbiota-
- derived acetate protects against respiratory syncytial virus infection through a GPR43-type
- 1 interferon response. *Nat Commun* (2019) **10**:3273. doi:10.1038/s41467-019-11152-6
- 21. Ngo VL, Lieber CM, Kang H-J, Sakamoto K, Kuczma M, Plemper RK, et al. Intestinal
- 618 microbiota programming of alveolar macrophages influences severity of respiratory viral
- infection. *Cell Host Microbe* (2024) **32**:335-348.e8. doi:10.1016/j.chom.2024.01.002
- 620 22. Harding JN, Siefker D, Vu L, You D, DeVincenzo J, Pierre JF, et al. Altered gut microbiota
- in infants is associated with respiratory syncytial virus disease severity. BMC Microbiol
- 622 (2020) **20**:140. doi:10.1186/s12866-020-01816-5
- 23. Zhao Y, Dong BR, Hao Q. Probiotics for preventing acute upper respiratory tract infections.
- 624 Cochrane Database Syst Rev (2022) 8:CD006895.
- doi:10.1002/14651858.CD006895.pub4
- 626 24. Du T, Lei A, Zhang N, Zhu C. The Beneficial Role of Probiotic Lactobacillus in Respiratory
- Diseases. Front Immunol (2022) **13**:908010. doi:10.3389/fimmu.2022.908010
- 628 25. Shi HY, Zhu X, Li WL, Mak JW, Wong SH, Zhu ST, et al. Modulation of gut microbiota
- protects against viral respiratory tract infections: a systematic review of animal and clinical
- studies. *Eur J Nutr* (2021) **60**:4151–74. doi:10.1007/s00394-021-02519-x
- 26. Nesbitt H, Burke C, Haghi M. Manipulation of the Upper Respiratory Microbiota to Reduce
- Incidence and Severity of Upper Respiratory Viral Infections: A Literature Review. Front
- 633 *Microbiol* (2021) **12**:713703. doi:10.3389/fmicb.2021.713703

- 634 27. Harper A, Vijayakumar V, Ouwehand AC, Haar J ter, Obis D, Espadaler J, et al. Viral
- Infections, the Microbiome, and Probiotics. Front Cell Infect Microbiol (2020) **10**:596166.
- 636 doi:10.3389/fcimb.2020.596166
- 28. Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics.
- 638 Nat Med (2019) **25**:716–29. doi:10.1038/s41591-019-0439-x
- 639 29. Rasmussen KM, Catalano PM, Yaktine AL. New guidelines for weight gain during
- pregnancy: what obstetrician/gynecologists should know. Curr Opin Obstet Gynecol
- 641 (2009) **21**:521–6. doi:10.1097/GCO.0b013e328332d24e
- 30. Martens A, Amann G, Schmidt K, Gaupmann R, Böhm B, Dehlink E, et al. An optimized,
- robust and reproducible protocol to generate well-differentiated primary nasal epithelial
- models from extremely premature infants. Sci Rep (2019) 9:20069. doi:10.1038/s41598-
- 645 019-56737-9
- 31. Jonsdottir HR, Dijkman R. Characterization of human coronaviruses on well-differentiated
- 647 human airway epithelial cell cultures. *Methods Mol Biol* (2015) **1282**:73–87.
- 648 doi:10.1007/978-1-4939-2438-7 8
- 32. Schreiber A, Viemann D, Schöning J, Schloer S, Mecate Zambrano A, Brunotte L, et al.
- The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates
- pro-inflammatory cytokine/chemokine responses. Cell Mol Life Sci (2022) 79:65.
- doi:10.1007/s00018-021-04085-1
- 653 33. Sake SM, Zhang X, Rajak MK, Urbanek-Quaing M, Carpentier A, Gunesch AP, et al. Drug
- repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein
- 655 inhibitor. Nat Commun (2024) **15**:1173. doi:10.1038/s41467-024-45241-y
- 656 34. Domenico E de, Bonaguro L, Schulte-Schrepping J, Becker M, Händler K, Schultze JL.
- Optimized workflow for single-cell transcriptomics on infectious diseases including COVID-
- 19. STAR Protoc (2020) 1:100233. doi:10.1016/j.xpro.2020.100233
- 35. Essaidi-Laziosi M, Brito F, Benaoudia S, Royston L, Cagno V, Fernandes-Rocha M, et al.
- Propagation of respiratory viruses in human airway epithelia reveals persistent virus-

- specific signatures. *J Allergy Clin Immunol* (2018) **141**:2074–84.
- doi:10.1016/j.jaci.2017.07.018
- 36. Iverson E, Kaler L, Agostino EL, Song D, Duncan GA, Scull MA. Leveraging 3D Model
- Systems to Understand Viral Interactions with the Respiratory Mucosa. *Viruses* (2020) **12**.
- 665 doi:10.3390/v12121425
- 37. Viemann D. S100-Alarmins Are Essential Pilots of Postnatal Innate Immune Adaptation.
- *Front Immunol* (2020) **11**:688. doi:10.3389/fimmu.2020.00688
- 38. Willers M, Ulas T, Völlger L, Vogl T, Heinemann AS, Pirr S, et al. S100A8 and S100A9 Are
- Important for Postnatal Development of Gut Microbiota and Immune System in Mice and
- 670 Infants. *Gastroenterology* (2020) **159**:2130-2145.e5. doi:10.1053/j.gastro.2020.08.019
- 39. Dirks J, Andres O, Paul L, Manukjan G, Schulze H, Morbach H. IgD shapes the pre-
- immune naïve B cell compartment in humans. Front Immunol (2023) **14**:1096019.
- 673 doi:10.3389/fimmu.2023.1096019
- 40. Dirks J, Viemann D, Beyersdorf N, Härtel C, Morbach H. Insights into B-cell ontogeny
- 675 inferred from human immunology. *Eur J Immunol* (2023) **53**:e2250116.
- 676 doi:10.1002/eji.202250116
- 41. León-Lara X, Fichtner AS, Willers M, Yang T, Schaper K, Riemann L, et al. γδ T cell
- profiling in a cohort of preterm infants reveals elevated frequencies of CD83+ γδ T cells in
- sepsis. *J Exp Med* (2024) **221**. doi:10.1084/jem.20231987
- 680 42. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell
- subpopulations from infancy to adulthood. Clin Exp Immunol (2010) 162:271–9.
- 682 doi:10.1111/j.1365-2249.2010.04206.x
- 43. Ravens S, Fichtner AS, Willers M, Torkornoo D, Pirr S, Schöning J, et al. Microbial
- exposure drives polyclonal expansion of innate γδ T cells immediately after birth. *Proc Natl*
- 685 Acad Sci U S A (2020) **117**:18649–60. doi:10.1073/pnas.1922588117
- 44. Austermann J, Friesenhagen J, Fassl SK, Petersen B, Ortkras T, Burgmann J, et al.
- Alarmins MRP8 and MRP14 induce stress tolerance in phagocytes under sterile
- inflammatory conditions. *Cell Rep* (2014) **9**:2112–23. doi:10.1016/j.celrep.2014.11.020

- 45. Ulas T, Pirr S, Fehlhaber B, Bickes MS, Loof TG, Vogl T, et al. S100-alarmin-induced
- innate immune programming protects newborn infants from sepsis. *Nat Immunol* (2017)
- **18**:622–32. doi:10.1038/ni.3745
- 46. Holsten L, Dahm K, Oestreich M, Becker M, Ulas T. hCoCena: A toolbox for network-
- based co-expression analysis and horizontal integration of transcriptomic datasets. STAR
- 694 *Protoc* (2024) **5**:102922. doi:10.1016/j.xpro.2024.102922
- 695 47. Oestreich M, Holsten L, Agrawal S, Dahm K, Koch P, Jin H, et al. hCoCena: horizontal
- integration and analysis of transcriptomics datasets. *Bioinformatics* (2022) **38**:4727–34.
- doi:10.1093/bioinformatics/btac589
- 698 48. Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, Markó L, Aron-Wisnewsky J,
- Nielsen T, et al. Combinatorial, additive and dose-dependent drug-microbiome
- associations. *Nature* (2021) **600**:500–5. doi:10.1038/s41586-021-04177-9
- 701 49. Chen C-Y, Löber U, Forslund SK. LongDat: an R package for covariate-sensitive
- longitudinal analysis of high-dimensional data. *Bioinform Adv* (2023) **3**:vbad063.
- 703 doi:10.1093/bioadv/vbad063
- 50. Amir A, Erez-Granat O, Braun T, Sosnovski K, Hadar R, BenShoshan M, et al. Gut
- microbiome development in early childhood is affected by day care attendance. NPJ
- 706 Biofilms Microbiomes (2022) 8:2. doi:10.1038/s41522-021-00265-w
- 51. Stewart CJ, Ajami NJ, O'Brien JL, Hutchinson DS, Smith DP, Wong MC, et al. Temporal
- development of the gut microbiome in early childhood from the TEDDY study. *Nature*
- 709 (2018) **562**:583–8. doi:10.1038/s41586-018-0617-x
- 710 52. Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. The
- 711 WHO estimates of excess mortality associated with the COVID-19 pandemic. *Nature*
- 712 (2023) **613**:130–7. doi:10.1038/s41586-022-05522-2
- 713 53. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden
- of respiratory syncytial virus infection in young children. *N Engl J Med* (2009) **360**:588–98.
- 715 doi:10.1056/NEJMoa0804877

- 54. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and
- 717 national disease burden estimates of acute lower respiratory infections due to respiratory
- syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*
- 719 (2022) **399**:2047–64. doi:10.1016/S0140-6736(22)00478-0
- 720 55. Zhang Q, Bastard P, Cobat A, Casanova J-L. Human genetic and immunological
- determinants of critical COVID-19 pneumonia. *Nature* (2022) **603**:587–98.
- 722 doi:10.1038/s41586-022-04447-0
- 56. Forbester JL, Humphreys IR. Genetic influences on viral-induced cytokine responses in
- 724 the lung. *Mucosal Immunol* (2021) **14**:14–25. doi:10.1038/s41385-020-00355-6
- 57. Brandstetter S, Toncheva AA, Niggel J, Wolff C, Gran S, Seelbach-Göbel B, et al. KUNO-
- Kids birth cohort study: rationale, design, and cohort description. *Mol Cell Pediatr* (2019)
- 727 **6**:1. doi:10.1186/s40348-018-0088-z
- 728 58. Pangratz-Fuehrer S, Genzel-Boroviczény O, Bodensohn WE, Eisenburger R,
- Scharpenack J, Geyer PE, et al. Cohort profile: the MUNICH Preterm and Term Clinical
- study (MUNICH-PreTCl), a neonatal birth cohort with focus on prenatal and postnatal
- determinants of infant and childhood morbidity. BMJ Open (2021) 11:e050652.
- 732 doi:10.1136/bmjopen-2021-050652
- 59. Fransson E, Gudnadottir U, Hugerth LW, Itzel EW, Hamsten M, Boulund F, et al. Cohort
- 734 profile: the Swedish Maternal Microbiome project (SweMaMi) assessing the dynamic
- associations between the microbiome and maternal and neonatal adverse events. *BMJ*
- 736 *Open* (2022) **12**:e065825. doi:10.1136/bmjopen-2022-065825
- 737 60. Pandolfini C, Clavenna A, Cartabia M, Campi R, Bonati M. National, longitudinal NASCITA
- birth cohort study to investigate the health of Italian children and potential influencing
- factors. *BMJ Open* (2022) **12**:e063394. doi:10.1136/bmjopen-2022-063394
- 740 61. Bohmwald K, Gálvez NM, Canedo-Marroquín G, Pizarro-Ortega MS, Andrade-Parra C,
- Gómez-Santander F, et al. Contribution of Cytokines to Tissue Damage During Human
- 742 Respiratory Syncytial Virus Infection. Front Immunol (2019) 10:452.
- 743 doi:10.3389/fimmu.2019.00452

- 744 62. Dunning J, Blankley S, Hoang LT, Cox M, Graham CM, James PL, et al. Progression of
- 745 whole-blood transcriptional signatures from interferon-induced to neutrophil-associated
- patterns in severe influenza. Nat Immunol (2018) 19:625-35. doi:10.1038/s41590-018-
- 747 0111-5
- 748 63. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo
- characterization of new swine-origin H1N1 influenza viruses. *Nature* (2009) **460**:1021–5.
- 750 doi:10.1038/nature08260
- 751 64. To KK, Hung IF, Li IW, Lee K-L, Koo C-K, Yan W-W, et al. Delayed clearance of viral load
- and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus
- 753 infection. *Clin Infect Dis* (2010) **50**:850–9. doi:10.1086/650581
- 65. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. *Nat Rev Immunol* (2014)
- 755 **14**:315–28. doi:10.1038/nri3665
- 756 66. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for
- 757 monocytes and macrophages. *Nat Rev Immunol* (2020) **20**:355–62. doi:10.1038/s41577-
- 758 020-0331-4
- 759 67. O'Neill MB, Quach H, Pothlichet J, Aquino Y, Bisiaux A, Zidane N, et al. Single-Cell and
- Bulk RNA-Sequencing Reveal Differences in Monocyte Susceptibility to Influenza A Virus
- 761 Infection Between Africans and Europeans. Front Immunol (2021) 12:768189.
- 762 doi:10.3389/fimmu.2021.768189
- 68. Reyman M, van Houten MA, van Baarle D, Bosch, Astrid A T M, Man WH, Chu, Mei Ling
- J N, et al. Impact of delivery mode-associated gut microbiota dynamics on health in the
- 765 first year of life. *Nat Commun* (2019) **10**:4997. doi:10.1038/s41467-019-13014-7
- 69. Alba C, Aparicio M, González-Martínez F, González-Sánchez MI, Pérez-Moreno J, Del
- Toledo Castillo B, et al. Nasal and Fecal Microbiota and Immunoprofiling of Infants With
- 768 and Without RSV Bronchiolitis. Front Microbiol (2021) 12:667832.
- 769 doi:10.3389/fmicb.2021.667832
- 770 70. Følsgaard NV, Schjørring S, Chawes BL, Rasmussen MA, Krogfelt KA, Brix S, et al.
- 771 Pathogenic bacteria colonizing the airways in asymptomatic neonates stimulates topical

inflammatory mediator release. Am J Respir Crit Care Med (2013) 187:589-95.

doi:10.1164/rccm.201207-1297OC

773

## Table 1 Baseline characteristics of the MIAI cohort

Total number	171
Sex, female (%)	85 (49.7)
Gestational age [weeks] (SD)	39.8 (± 1.2)
Mode of delivery	
VD (%) CS total (%)	106 (62) 65 (38)
. ,	(00)
Multiples Singles (%)	160 (06)
Multiples (%)	160 (96) 6 (4)
Antenatal corticosteroids	4 (2.4)
Mean umbilical cord arterial pH (SD)	7.2 (± 0.1)
APGAR score	
Mean APGAR at 1 min (SD)	8.9 (± 0.9)
Mean APGAR at 5 min (SD)	9.7 (± 0.5)
Mean APGAR at 10 min (SD)	9.9 (± 0.3)
Premature rupture of membranes (%)	47 (27)
Bonding in the delivery room (%)	163 (95)
Mean birth weight [g] (SD)	3429 (± 459)
Mean percentile birth weight [g] (SD)	54 (29)
Mean birth length [cm] (SD)	51 (± 2.0)
Mead head circumference at birth [cm] (SD)	34.9 (± 1.4)
SGA (%)	14 (9)
LGA (%)	24 (14)
Siblings	
None (%)	85 (50)
One (%)	67 (39)
Two or more (%)	19 (11)
Siblings in child care or school (%)	74 (43)
Mean number household members (SD)	3.6 (± 0.7)
Smoking in family (%)	37 (22)
Pets (%)	37 (22)

Environment	
Rural (%)	84 (49)
Urban (%)	87 (51)

SD, standard deviation; CS, cesarean section; VD, vaginal delivery; SGA, small for gestational age; LGA, large for gestational age

# Table 2 Baseline characteristics of pregnancy in the MIAI cohort

	Mothers
Total number	166
Mean body weight before pregnancy [kg] (SD)	68.7 (± 15.2)
Mean BMI before pregnancy (SD)	24.6 (± 5.9)
Mean body weight at delivery [kg] (SD)	82.7 (± 16.4)
Mean BMI at delivery (SD)	29.4 (± 5.8)
Previous deliveries	
One (%)	67 (40)
Two or more (%)	20 (12)
Previous pregnancies	53 (32)
One (%)	49 (30)
Two or more (%)	40 (00)
Blood type	
A (%)	68 (41)
B (%)	20 (12)
AB (%)	6 (3.6)
0 (%)	72 (43)
Rhesus factor	
Positive (%)	142 (86)
Negative (%)	24 (14)
Diet	
Vegetarian (%)	13 (8)
Vegan (%)	0 (0.0)
Other (%)	4 (2.4)
Gestational diabetes mellitus	
Diet-controlled (%)	16 (10)
Insulin-treated (%)	4 (2.4)
Gestational hypertension (%)	3 (1.8)
Preeclampsia (%)	0 (0.0)
CMV status	
Negative (%)	68 (41)
Positive (%)	19 (11)
Unknown (%)	79 (48)
HBV status	
Negative (%)	84 (51)

Positive (%)	1 (0.6)
Unknown (%)	9 (5.4)
Vaccinated (%)	72 (43)
Influenza status	
Unknown (%)	87 (52)
Recovered (%)	2 (1.2)
Vaccinated (%)	74 (45)
Recovered and vaccinated	3 (1.8)
SARS-CoV-2 status	
Unknown (%)	5 (3.0)
Recovered (%)	5 (3.0)
Vaccinated (%)	42 (25)
Recovered and vaccinated (%)	114 (69)
Respiratory tract infections during pregnancy (%)	78 (47)
Antibiotic treatment during pregnancy (%)	38 (23)
Long-term medication during pregnancy (%)	37 (22)
Nicotine abuse	
Smoking (%)	3 (1.8)
No smoking (%)	163 (98)

BMI, Body mass index; CMV, Cytomegalovirus; HBV, Hepatitis B virus

780

## Table 3 Baseline characteristics of the parents in the MIAI cohort

782

	Mothers	Fathers
Total number	166	164*
Mean age at delivery (SD)	32.8 (± 4.5)	35.3 (± 5.4)
Somatic disorders (%)	87 (52)	40 (24)
Mental disorders (%)	14 (8.4)	10 (6.0)
Smoker (%)	3 (1.8)	34 (21)
Origin		
Germany (%)	140 (84)	138 (84)
Asia (%)	7 (4.2)	5 (3.0)
Africa and Middle East (%)	6 (3.6)	8 (4.9)
Other (%)	13 (7.8)	13 (7.9)
Education		
Certificate <10 years school (%)	26 (16)	35 (21)
Certificate ≥10 years school (%)	131 (79)	116 (71)
No/other certificate (%)	9 (5.4)	13 (7.9)

<sup>\*</sup>In two cases, father unknown. SD, standard deviation

Table 4 Overview of study appointments and clinical data collected in MIAI

Age of the child	Day 1 - 3	Day 30 (-40)	Month 6 (-7)	Month 12 (-14)
Screening for enrollment	0	00 ( 40)	0(1)	12 ( 14)
Pregnancy and perinatal history				
History of diseases during pregnancy including gestational diabetes and hypertension, antenatal and perinatal	0			
antibiotics, mode of birth, multiplicity, sex, gestational age, umbilical artery pH and base excess, APGAR, body	U			
measurements, complications at delivery				
Physical examination child				
Total body physical examination, anthropometric measurements, blood pressure, respiratory rate,	0	0	0	0
neurodevelopmental milestones				
CRF child				
Body measurements and notes as documented in the child health record book by the attending pediatrician,				
history of vaccinations, infections, antibiotics including days of treatment, medication, inhalation, episodes of	0	0	0	0
wheezing, skin rashes, allergies, hospital stays, and surgical procedures, diet (exclusive breastfeeding, mixed	J		· ·	J
feeding with formula, age at introduction of solid food) and supplements, day care, lifestyle including further				
siblings, household members, pets, and residence (rural/urban), stays abroad, family history				
CRF mother				
Age, somatic or psychiatric diseases, previous pregnancies, height, weight before and at end of pregnancy,	0	0	0	0
BMI, CMV/HBV/HIV status, vaccination before and during pregnancy, blood type, infections, medication, diet,	J	J	J	J
smoking, ethnicity, educational level, lifestyle, family history, subjective stress level				
CRF father	0			
Age, somatic or psychiatric diseases, medication, smoking, ethnicity, educational level, lifestyle, family history	J			

Figure 1




Figure 2




Figure 3

